F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach.
Stefan T G BruijnenDurga M S H ChandrupatlaLeonardo GiovanonniDario NeriDanielle J VugtsMarc C HuismanOtto S HoekstraRené J P MustersAdriaan A LammertsmaGuus A M S van DongenGerrit JansenCarla F M MolthoffConny J van der LakenPublished in: Molecular pharmaceutics (2018)
Antibody fragment F8-mediated interleukin 10 (IL10) delivery is a novel treatment for rheumatoid arthritis (RA). F8 binds to the extra-domain-A of fibronectin (ED-A). In this study, in vivo biodistribution and arthritis targeting of radiolabeled F8-IL10 were investigated in RA patients, followed by further animal studies. Therefore, three RA patients (DAS28 > 3.2) received 0.4 mg of 30-74 megabecquerel [124I]I-F8-IL10 for PET-CT and blood sampling. In visually identified PET-positive joints, target-to-background was calculated. Healthy mice, rats, and arthritic rats were injected with iodinated F8-IL10 or KSF-IL10 control antibody. Various organs were excised, weighed, and counted for radioactivity. Tissue sections were stained for fibronectin ED-A. In RA patients, [124I]I-F8-IL10 was cleared rapidly from the circulation with less than 1% present in blood after 5 min. PET-CT showed targeting in 38 joints (11-15 per patient) and high uptake in the liver and spleen. Mean target-to-background ratios of PET-positive joints were 2.5 ± 1.2, 1.5 times higher for clinically active than clinically silent joints. Biodistribution of radioiodinated F8-IL10 in healthy mice showed no effect of the radioiodination method. [124I]I-F8-IL10 joint uptake was also demonstrated in arthritic rats, ∼14-fold higher than that of the control antibody [124I]I-KSF-IL10 ( p < 0.001). Interestingly, liver and spleen uptake were twice as high in arthritic than in healthy rats and were related to increased (∼7×) fibronectin ED-A expression in these tissues. In conclusion, [124I]I-F8-IL10 uptake was observed in arthritic joints in RA patients holding promise for visualization of inflamed joints by PET-CT imaging and therapeutic targeting. Patient observations and, subsequently, arthritic animal studies pointed to awareness of increased [124I]I-F8-IL10 uptake in the liver and spleen associated with moderate systemic inflammation. This translational study demonstrated the value of in vivo biodistribution and PET-CT-guided imaging in development of new and potential antirheumatic drugs'.
Keyphrases
- pet ct
- rheumatoid arthritis
- end stage renal disease
- positron emission tomography
- ejection fraction
- chronic kidney disease
- newly diagnosed
- disease activity
- emergency department
- computed tomography
- peritoneal dialysis
- type diabetes
- high resolution
- systemic lupus erythematosus
- systemic sclerosis
- prognostic factors
- drug delivery
- poor prognosis
- interstitial lung disease
- metabolic syndrome
- cancer therapy
- machine learning
- adipose tissue
- artificial intelligence
- drug induced
- risk assessment
- skeletal muscle
- mass spectrometry
- combination therapy